Decision Diagnostics Corp (DECN)

[IPwatcher]

t seems the Berman gang concluded the SEC and/or DOJ would not invest the time and/or effort needed to verify the bogus claims. I bet there are just a few people, you and I included, who could help clarify!

Well here is the first one:

Over the last 20 years, he sold
affordable and reliable diagnostic devices that helped diabetics monitor their blood glucose levels.
These devices worked using impedance spectroscopy, a sophisticated technology that can detect
the electrochemical signature of a blood sample

Smbg test strips of the type that DECN sold use "Electrochemical Amperometry" to do the actual glucose measurement, not EIS. And they have for years.
I think it was around the late 1990s or early 2000s that Roche improved their test strips with a (patented) impedance measurement that allowed a 'hematocrit' correction to be implemented by detecting the red blood cells in the sample and accounting for these in their calibrations, which lead to 'slightly' more accurate results in certain situations. Now whether you could go as far as to say that this impedance correction was actually "EIS spectroscopy" is a matter of semantics... and I would argue was hyperbole.... It was just an AC impedenace measurement. Nothing more.

Now the 'Genultimate' strips that Berman actually sold for use with the One Touch meters did not use ANY impedance based hematocrit correction at all... as those lifescan meters predated that technology becoming freely available, as it was still heavily protected by Roche patents when One Touch Ultra was launched.
Then in the late 2010s, the Roche patents started to term expire and some other manufacturers started exploiting the freedom to operate that this generaed, and they began including impedance based hematocrit correction into their own test systems. But these were basically knock-offs of Roche impedance technology. Old news.

And it was this knock off of twenty year old Roche impedance based hematocrit correction that Berman (or in reality Daniel KIM at the Bio co!) was trying to implement with his "New and groundbreaking" Genultimate TBG product family.
Except he never actually got as far as launching Genultimate TBG.... did he?
He never got it through the regulatory submissions and even if he had done, he was on a hiding to nothing as by then the market was already flooded with cheaper and better versions of the by now quite old smbg technology that Berman was trying to replicate. His smbg business was drying up, and his allegedly 'new' products were already looking pretty dated before he'd even got them off the ground!

But by now he had cooked up some trial meters with the Roche Impedance hematocrit correction capability in them.
And so he claimed he could use these to detect Covid virus in blood. The 'New Story that would allow him to raise millions'

But he couldn't
Firstly, he couldn't detect Covid 19 virus in blood. Because the virus wasn't present in the blood. It was not a blood borne pathogen
Secondly, I am pretty sure that if you COULD reliably detect covid virus with a modified knock off 20 years old Roche rip off glucose meter that easily.... If it was that easy, Roche would have done it!
But You can't. And they didn't!
Finally, while impedance spectrsocopy can detect all sorts of particles, based upon electrical properties and morphology, its really not that very good at distinguishing between them! Is that Covid, or toothpaste? Can't tell. There is a world of difference between a purified sample in a lab and a dirty sample in an endogenous environment.
Now with AI and/or incorporation of biorecognition chemsitry, you could theoretcially one day build an impedance based Covid virus detector, and that might one day work almost as well an immunoassay based lateral flow test.... Why would you?
Absolutely no advantage over a simple lateral flow immunoassay would be conferred by going down a much more technologically convoluted apporach. What would be the point?

In a nutshell, this is how that opening passage should actually read;

Over the last 20 years, he sold
generic test strips that helped diabetics monitor their blood glucose levels.
These devices worked without using any impedance spectroscopy, which is a technology that can detect
the impedance signature of a sample